Tilting the AXIS towards therapeutic limits in renal cancer

Lancet. 2011 Dec 3;378(9807):1898-900. doi: 10.1016/S0140-6736(11)61655-3. Epub 2011 Nov 4.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Axitinib
  • Benzenesulfonates / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Humans
  • Imidazoles / therapeutic use*
  • Indazoles / therapeutic use*
  • Kidney Neoplasms / drug therapy*
  • Male
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use*
  • Sorafenib

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Benzenesulfonates
  • Imidazoles
  • Indazoles
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Sorafenib
  • Axitinib